{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:00:49Z","timestamp":1779242449638,"version":"3.51.4"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Idiopathic photosensitive skin disorders, or idiopathic photodermatoses, are characterized by abnormal reactions to sunlight and ultraviolet (UV) radiation. They encompass conditions such as actinic prurigo, chronic actinic dermatitis, solar urticaria, photoaggravated psoriasis, polymorphic light eruption and photoaggravated eczema. Treatment options remain limited, but monoclonal antibodies (such as dupilumab, omalizumab, adalimumab, ustekinumab) and Janus kinase (JAK) inhibitors (such as tofacitinib, baricitinib, upadacitinib) have emerged as promising potential therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the short- and long-term efficacy of these biologics and JAK inhibitors in managing these conditions, despite their lack of formal approval.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A literature search was conducted using PubMed, Google Scholar and the Wiley Online Library. Inclusion criteria focused on studies published between 1960 and 2025 investigating monoclonal antibodies and JAK inhibitors for idiopathic photodermatoses, excluding other treatment modalities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-two studies involving 96 patients met the inclusion criteria. Most studies were case series or reports. Findings indicated significant reductions in disease activity and improvement in quality-of-life metrics (such as the Dermatology Life Quality Index) across various conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The lack of high-quality studies and the reliance on case reports limit generalizability. Variations in treatment regimens and outcome measures pose additional challenges. Monoclonal antibodies and JAK inhibitors demonstrate promise in reducing symptoms and improving quality of life in idiopathic photosensitive skin disorders. As these treatments are not formally indicated for these conditions, further research is warranted to confirm their efficacy and safety. This review highlights the need for clinical trials to enhance understanding and management of these challenging dermatological conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llaf487","type":"journal-article","created":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T12:46:37Z","timestamp":1762087597000},"page":"548-554","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of monoclonal antibodies and Janus kinase inhibitors in the treatment of idiopathic photosensitive skin disorders: a systematic review"],"prefix":"10.1093","volume":"51","author":[{"given":"Jana Faisal","family":"Alawadhi","sequence":"first","affiliation":[{"name":"Centre for Dermatology Research, Faculty of Biology, Medicine and Health, The University of Manchester and Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Ayer","sequence":"additional","affiliation":[{"name":"Centre for Dermatology Research, Faculty of Biology, Medicine and Health, The University of Manchester and Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"2026032611524302300_llaf487-B1","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/MOP.0000000000001155","article-title":"Photodermatoses: what\u2019s new","volume":"34","author":"Scollan","year":"2022","journal-title":"Curr Opin Pediatr"},{"key":"2026032611524302300_llaf487-B2","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1111\/jdv.15115","article-title":"Photodermatoses in skin of colour","volume":"32","author":"Gutierrez","year":"2018","journal-title":"J Eur Acad Dermatol\u00a0Venereol"},{"key":"2026032611524302300_llaf487-B3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-4362.1993.tb02805.x","article-title":"Photodermatosis. Part I: photobiology, photoimmunology, and idiopathic photodermatoses","volume":"32","author":"Ledo","year":"1993","journal-title":"Int J Dermatol"},{"key":"2026032611524302300_llaf487-B4","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1600-0781.2008.00375.x","article-title":"Actinic prurigo","volume":"24","author":"Ross","year":"2008","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2026032611524302300_llaf487-B5","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1365-4362.1995.tb04435.x","article-title":"Actinic prurigo: an update","volume":"34","author":"Hojyo-Tomoka","year":"1995","journal-title":"Int J Dermatol"},{"key":"2026032611524302300_llaf487-B6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.det.2014.03.007","article-title":"Chronic actinic dermatitis","volume":"32","author":"Paek","year":"2014","journal-title":"Dermatol Clin"},{"key":"2026032611524302300_llaf487-B7"},{"key":"2026032611524302300_llaf487-B8"},{"key":"2026032611524302300_llaf487-B9","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2026032611524302300_llaf487-B10","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/pde.14311","article-title":"Clearance of pediatric actinic prurigo with dupilumab","volume":"37","author":"Eickstaedt","year":"2020","journal-title":"Pediatr Dermatol"},{"key":"2026032611524302300_llaf487-B11","first-page":"471","article-title":"Dupilumab for the treatment of actinic prurigo","volume":"19","author":"Perz","year":"2021","journal-title":"Skinmed"},{"key":"2026032611524302300_llaf487-B12","doi-asserted-by":"crossref","first-page":"e13899","DOI":"10.1111\/cts.13899","article-title":"Dupilumab: mechanism of action, clinical, and translational science","volume":"17","author":"McCann","year":"2024","journal-title":"Clin Transl Sci"},{"key":"2026032611524302300_llaf487-B13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb","year":"2019","journal-title":"Clin Exp Allergy"},{"key":"2026032611524302300_llaf487-B14","first-page":"E297","article-title":"Reclaiming quality of life: a case of chronic actinic dermatitis successfully treated with dupilumab","volume":"190","author":"Bobotsis","year":"2018","journal-title":"CMAJ"},{"key":"2026032611524302300_llaf487-B15","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.2147\/CCID.S342401","article-title":"Successful treatment of chronic actinic dermatitis with dupilumab: a case report and review of the literature","volume":"14","author":"Chen","year":"2021","journal-title":"Clin Cosmet Invest Dermatol"},{"key":"2026032611524302300_llaf487-B16","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.2147\/CCID.S422683","article-title":"The effectiveness and safety of dupilumab for the treatment of recalcitrant chronic actinic dermatitis: a case series","volume":"16","author":"Chen","year":"2023","journal-title":"Clin Cosmet Invest Dermatol"},{"key":"2026032611524302300_llaf487-B17","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/phpp.12566","article-title":"Dupilumab for the treatment of chronic actinic dermatitis","volume":"36","author":"Patel","year":"2020","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2026032611524302300_llaf487-B18","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jdcr.2019.05.006","article-title":"Dupilumab for the treatment of severe photodermatitis","volume":"5","author":"Smith","year":"2019","journal-title":"JAAD Case Reports"},{"key":"2026032611524302300_llaf487-B19","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/phpp.12851","article-title":"Chronic actinic dermatitis successfully treated with methotrexate and dupilumab","volume":"39","author":"McFeely","year":"2023","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2026032611524302300_llaf487-B20","doi-asserted-by":"crossref","first-page":"2050313X19845235","DOI":"10.1177\/2050313X19845235","article-title":"A case report of therapeutically challenging chronic actinic dermatitis","volume":"7","author":"Verma","year":"2019","journal-title":"SAGE Open Med Case Rep"},{"issue":"Suppl. 1","key":"2026032611524302300_llaf487-B21","first-page":"98","article-title":"PD08 Efficacy of dupilumab in chronic actinic dermatitis","volume":"183","author":"Salam","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026032611524302300_llaf487-B22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/bjd\/ljae180","article-title":"Dupilumab in chronic actinic dermatitis: a retrospective case series","volume":"191","author":"O\u2019Reilly","year":"2024","journal-title":"Br J Dermatol"},{"key":"2026032611524302300_llaf487-B23","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/ajd.14293","article-title":"Dupilumab for chronic actinic dermatitis: a case series and review of the literature","volume":"65","author":"Holmes","year":"2024","journal-title":"Australas J Dermatol"},{"key":"2026032611524302300_llaf487-B24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jdcr.2024.01.039","article-title":"Dupilumab as treatment of actinic prurigo suggests pathophysiologic mechanism of disease: a case series","volume":"46","author":"Barker","year":"2024","journal-title":"JAAD Case Reports"},{"key":"2026032611524302300_llaf487-B25","doi-asserted-by":"crossref","first-page":"166","DOI":"10.4103\/ds.DS-D-22-00172","article-title":"Dupilumab for patients with photoaggravated dermatoses with skin nodules as main manifestations: a case series","volume":"41","author":"Ruxian","year":"2023","journal-title":"Dermatologica Sinica"},{"key":"2026032611524302300_llaf487-B26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/phpp.12814","article-title":"Polymorphous light eruption treated with omalizumab","volume":"39","author":"Sope\u00f1a","year":"2022","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2026032611524302300_llaf487-B27","volume-title":"Omalizumab","author":"Kumar","year":"2023"},{"key":"2026032611524302300_llaf487-B28","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.jaci.2020.10.033","article-title":"Omalizumab in \u201cnon-IgE-mediated\u201d diseases","volume":"147","author":"Chinthrajah","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2026032611524302300_llaf487-B29","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/phpp.12370","article-title":"Clinical and photobiological response in eight patients with solar urticaria under treatment with omalizumab, and review of the literature","volume":"34","author":"Morgado-Carrasco","year":"2018","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2026032611524302300_llaf487-B30","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jaci.2009.11.007","article-title":"Partial improvement of solar urticaria after omalizumab","volume":"125","author":"Waibel","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"2026032611524302300_llaf487-B31","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.jaip.2018.02.032","article-title":"Omalizumab for the treatment of solar urticaria: case series and systematic review of the literature","volume":"6","author":"Snast","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026032611524302300_llaf487-B32","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1590\/abd1806-4841.20198109","article-title":"Incapacitating solar urticaria: successful treatment with omalizumab","volume":"94","author":"Kieselova","year":"2019","journal-title":"An Bras Dermatol"},{"key":"2026032611524302300_llaf487-B33","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1111\/ced.13960","article-title":"Real-life experience in the treatment of solar urticaria: retrospective cohort study","volume":"44","author":"Snast","year":"2019","journal-title":"Clin Exp Dermatol"},{"issue":"Suppl.","key":"2026032611524302300_llaf487-B34","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.anai.2022.08.838","article-title":"Successful treatment of solar urticaria with omalizumab","volume":"129","author":"Mullur","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2026032611524302300_llaf487-B35","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaad.2019.05.070","article-title":"Clinical response and long-term follow-up of 20 patients with refractory solar urticaria under treatment with omalizumab","volume":"88","author":"Morgado-Carrasco","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2026032611524302300_llaf487-B36","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13052-021-01151-z","article-title":"Long term treatment with omalizumab in adolescent with refractory solar urticaria","volume":"47","author":"Iannelli","year":"2021","journal-title":"Ital J Pediatr"},{"key":"2026032611524302300_llaf487-B37","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/phpp.12132","article-title":"Complete primary treatment failure of adalimumab in a patient with photoaggravated psoriasis","volume":"31","author":"Kulapatrapa","year":"2014","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2026032611524302300_llaf487-B38","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jdcr.2016.09.008","article-title":"Tofacitinib citrate for the treatment of refractory, severe chronic actinic dermatitis","volume":"3","author":"Vesely","year":"2017","journal-title":"JAAD Case Reports"},{"key":"2026032611524302300_llaf487-B39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ced\/llad348","article-title":"JAK-ing up chronic actinic dermatitis with upadacitinib","volume":"49","author":"Pappa","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"2026032611524302300_llaf487-B40","volume-title":"Baricitinib","author":"Ahmad","year":"2025"},{"key":"2026032611524302300_llaf487-B41","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol Rev"},{"issue":"Suppl. 1","key":"2026032611524302300_llaf487-B42","doi-asserted-by":"crossref","first-page":"ljaf085.256","DOI":"10.1093\/bjd\/ljaf085.256","article-title":"PD04 Shining a light on eczema: a prospective, comparative, cohort study of dupilumab and Janus kinase inhibitors in photosensitive atopic dermatitis","volume":"193","author":"Khoursheed","year":"2025","journal-title":"Br J Dermatol"},{"key":"2026032611524302300_llaf487-B43","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2147\/CCID.S451824","article-title":"Successful treatment of chronic actinic dermatitis with tofacitinib","volume":"17","author":"Zhong","year":"2024","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2026032611524302300_llaf487-B44","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1097\/MJT.0000000000001616","article-title":"Improvement of refractory chronic actinic dermatitis during tofacitinib treatment","volume":"30","author":"Wang","year":"2023","journal-title":"Am J Ther"},{"key":"2026032611524302300_llaf487-B45","doi-asserted-by":"crossref","first-page":"600","DOI":"10.25259\/IJDVL_744_2022","article-title":"Recalcitrant chronic actinic dermatitis responding to tofacitinib: a case report","volume":"89","author":"Dev","year":"2023","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"2026032611524302300_llaf487-B46","doi-asserted-by":"crossref","first-page":"e15467","DOI":"10.1111\/dth.15467","article-title":"Tofacitinib in resistant chronic actinic dermatitis: a case series","volume":"35","author":"Majid","year":"2022","journal-title":"Dermatol Ther"},{"key":"2026032611524302300_llaf487-B47","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1002\/ski2.243","article-title":"Remission of chronic actinic dermatitis on baricitinib: a case report","volume":"3","author":"Maguire","year":"2023","journal-title":"Skin Health Dis"},{"key":"2026032611524302300_llaf487-B48","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1089\/derm.2023.0360","article-title":"Tofacitinib: a treatment option for recalcitrant polymorphic light eruption and its mechanistic rationale","volume":"35","author":"Sardana","year":"2024","journal-title":"Dermatitis"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf487\/65180022\/llaf487.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/4\/548\/65180022\/llaf487.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/4\/548\/65180022\/llaf487.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T15:52:54Z","timestamp":1774540374000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/4\/548\/8314262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":48,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,11,4]]},"published-print":{"date-parts":[[2026,3,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf487","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2025,11,4]]}}}